Sinovac Biotech Ltd.
SVA · NASDAQ
6/30/2024 | 12/31/2023 | 6/30/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | – | $307,865 | $140,404 | $280,471 |
| % Growth | – | 119.3% | -49.9% | – |
| Cost of Goods Sold | – | $0 | $188,409 | $430,094 |
| Gross Profit | – | $307,865 | -$48,005 | -$149,623 |
| % Margin | – | 100% | -34.2% | -53.3% |
| R&D Expenses | – | $193,383 | $151,132 | $257,714 |
| G&A Expenses | – | $0 | $0 | $0 |
| SG&A Expenses | – | $176,932 | $231,434 | $671,124 |
| Sales & Mktg Exp. | – | $0 | $0 | $0 |
| Other Operating Expenses | – | $0 | $0 | $0 |
| Operating Expenses | – | $370,315 | $382,566 | $928,838 |
| Operating Income | – | -$123,046 | -$430,571 | -$1,078,461 |
| % Margin | – | -40% | -306.7% | -384.5% |
| Other Income/Exp. Net | – | $33,622 | $413,892 | $508,960 |
| Pre-Tax Income | – | -$89,424 | -$16,679 | -$569,501 |
| Tax Expense | – | $138,918 | -$33,597 | -$198,855 |
| Net Income | – | -$116,836 | $16,918 | -$370,646 |
| % Margin | – | -38% | 12% | -132.2% |
| EPS | – | -1.17 | 0.17 | -3.73 |
| % Growth | – | -788.2% | 104.6% | – |
| EPS Diluted | – | -1.17 | 0.15 | -3.73 |
| Weighted Avg Shares Out | – | 99,604 | 99,577 | 99,502 |
| Weighted Avg Shares Out Dil | – | 99,604 | 114,227 | 99,502 |
| Supplemental Information | – | – | – | – |
| Interest Income | – | $55,525 | $29,589 | $106,820 |
| Interest Expense | – | $1,996 | $264 | $641 |
| Depreciation & Amortization | – | $60,596 | $84,149 | -$4,697 |
| EBITDA | – | -$26,832 | $20,803 | -$999,623 |
| % Margin | – | -8.7% | 14.8% | -356.4% |